Ameesh Isath

Sep 9, 2024 | onlinelibrary.wiley.com | Ameesh Isath |Mandeep R. Mehra

Invited Editorial The persistent poor prognosis in cardiogenic shock: Insights from recent trials Extracorporeal membrane oxygenation in the therapy of cardiogenic shock: 1-year outcomes of the multicentre, randomized ECMO-CS trial Petr Ostadal, Richard Rokyta, Jiri Karasek, Andreas Kruger, Dagmar Vondrakova, Marek Janotka, Jan Naar, Jana Smalcova, Marketa Hubatova, Milan Hromadka, Stefan Volovar, Miroslava Seyfrydova, Ales Linhart, Jan Belohlavek, for the ECMO-CS Investigators, European...

Mar 10, 2023 | onlinecjc.ca | Ameesh Isath |Aaqib H Malik |Dhrubajyoti Bandyopadhyay |Akshay Goel

Footnotes Disclosures Dr. Bhatt discloses the following relationships - Advisory Board: AngioWave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys; Board of Directors: AngioWave (stock options), Boston VA Research Institute, Bristol Myers Squibb (stock), DRS.LINQ (stock options),...

Feb 23, 2023 | onlinecjc.ca | Ameesh Isath |Aaqib H Malik |Dhrubajyoti Bandyopadhyay |Akshay Goel |Adrija Hajra |Alan Gass | +2 more

Prior studies have established the increased susceptibility of patients with cardiovascular comorbidities to COVID-19 and associated worse outcomes.1,2 Heart transplant (HT) recipients often have an increased burden of comorbidities and are also on chronic immunosuppressive therapies. Immunosuppression can increase susceptibility to infections but has also been hypothesized to blunt the cytokine storm in COVID-19 patients.